We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
101
Novavax
NVAX
$1.21B
$3.73M 0.15%
+26,352
New +$5.91M
ASXC
102
DELISTED
Asensus Surgical, Inc.
ASXC
$3.6M 0.15%
122,394
-7,283
-6% -$270K
NWBO
103
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$3.58M 0.15%
572,518
+244,118
+74% +$2.28M
VRTX icon
104
CALL
Vertex Pharmaceuticals
VRTX
$124B
$3.55M 0.15%
341
+206
+153% +$26.5K
ENDP
105
DELISTED
Endo International plc
ENDP
$3.51M 0.14%
50,658
+13,300
+36% +$1.06M
BLUE
106
PUT
DELISTED
bluebird bio
BLUE
$3.47M 0.14%
31
-38
-55% -$69.3K
NVRO
107
PUT
DELISTED
NEVRO CORP.
NVRO
$3.46M 0.14%
+745
New +$36.1K
SKY icon
108
Champion Homes
SKY
$4.58B
$3.45M 0.14%
+447,944
New +$1.41M
INDP icon
109
Indaptus Therapeutics
INDP
$231M
$3.44M 0.14%
+274
New +$3.6M
DVAX
110
DELISTED
Dynavax Technologies
DVAX
$3.31M 0.14%
134,954
+64,954
+93% +$1.84M
HZNP
111
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 0.14%
+1,658
New +$52.4K
HZNP
112
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.26M 0.13%
+164,658
New +$5.2M
FOLD
113
PUT
DELISTED
Amicus Therapeutics
FOLD
$3.25M 0.13%
2,322
+1,065
+85% +$16.7K
IOVA icon
114
Iovance Biotherapeutics
IOVA
$2.1B
$3.24M 0.13%
561,894
+134,650
+32% +$1.05M
ZLTQ
115
CALL
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.2M 0.13%
+1,000
New +$33.1K
AXN
116
DELISTED
Aoxing Pharmaceutical Company Inc.
AXN
$3.16M 0.13%
+2,134,054
New +$3.36M
VRTX icon
117
Vertex Pharmaceuticals
VRTX
$124B
$3.12M 0.13%
+30,000
New +$3.85M
MBLY
118
CALL
DELISTED
Mobileye N.V.
MBLY
$3.12M 0.13%
686
-1,860
-73% -$102K
BNTC icon
119
Benitec Biopharma
BNTC
$408M
$3.11M 0.13%
+1,981
New +$3.7M
PTCT icon
120
CALL
PTC Therapeutics
PTCT
$6.25B
$3.1M 0.13%
1,161
+550
+90% +$23.5K
LRMR icon
121
CALL
Larimar Therapeutics
LRMR
$398M
$3.07M 0.13%
80
+71
+789% +$32K
CEMP
122
PUT
DELISTED
Cempra, Inc.
CEMP
$3.01M 0.12%
+1,082
New +$40.2K
NVAX icon
123
CALL
Novavax
NVAX
$1.21B
$2.84M 0.12%
201
-34
-14% -$7.62K
CYH icon
124
PUT
Community Health Systems
CYH
$393M
$2.83M 0.12%
801
-54
-6% -$2.48K
LXRX icon
125
Lexicon Pharmaceuticals
LXRX
$1.04B
$2.81M 0.12%
261,595
-57,180
-18% -$624K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.